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EVALUATING DISEASE CAUSATION IN 
HUMANS EXPOSED TO TOXIC SUBSTANCES 
 
Joseph V. Rodricks, Ph.D., D.A.B.T. * 
INTRODUCTION 
Individuals claiming they have been harmed by exposures to 
chemical substances may seek compensation by bringing lawsuits 
against those whose actions caused the exposures to occur. 
Exposures may involve specific products, such as pharmaceuticals, 
foods and many other consumer products, or industrial chemicals 
used by workers in commercial operations of many types, or 
chemicals emitted to the environment during their manufacture, 
distribution, use, or disposal. Under our judicial system, those 
making claims of harm, i.e. plaintiffs, are generally required to 
offer evidence, through experts in medicine, epidemiology, 
toxicology, and perhaps several other scientific disciplines, that a 
causal relationship exists between the exposures they have 
allegedly experienced and the specific type of medical injury or 
disease they claim to have incurred. Defendants in such cases will 
also seek out experts to evaluate and, if possible, counter the 
evaluations of experts engaged by plaintiffs. Plaintiffs are 
generally not faced with the scientifically impossible burden of 
demonstrating causality with absolute proof; rather, the legal 
standard is typically expressed as a need to demonstrate that 
causality is demonstrable with a reasonable degree of scientific 
certainty, or that it is more likely true than not true that the harm 
                                                          
* Joseph V. Rodricks is a Founding Principal in the Arlington, Virginia 
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was caused by the exposure at issue.1 
This paper is devoted to certain aspects of the problem of 
evaluating disease causality in individuals when the putative cause 
is a chemical substance. Not all of the elements of a causality 
analysis will be discussed, must notably those concerning medical 
diagnosis of a plaintiff’s condition and the often complex and 
multifaceted problem of evaluating the nature, timing and 
magnitude of the plaintiff’s exposure to the chemical(s) of interest. 
Exposure analysis, which is a critical component of the evaluation 
of causation, may be relatively straightforward in the case of 
certain products, but may become exceedingly complex if it 
involves reconstructing exposures arising from contaminated 
environments, especially when there is evidence that the exposures 
have been ongoing for long periods of time. Experts in exposure 
evaluation come from many disciplines—chemistry, chemical and 
environmental engineering, modeling of the movement of 
chemicals through air or water or into the food supply, and 
industrial hygiene—and even a partial discussion of the nature of 
their work would significantly distract from the principal concerns 
of this paper. For this presentation it is assumed that accurate 
medical diagnoses can be achieved, and that reasonably accurate 
estimates of plaintiff’s exposures can be derived. 
The subjects of this paper pertain to the types of scientific 
evidence that are useful for a determination of general causation 
and specific causation, and of methods appropriate to evaluate that 
evidence. The question of general causation is directed at an 
evaluation of evidence that the chemical(s) at issue has been 
established, through appropriate scientific studies, to cause the type 
of injury or disease the plaintiff has developed. In the absence of 
convincing evidence of general causation, it would not be possible 
for a plaintiff, on the basis of the best available scientific 
knowledge, to make a reasonably convincing case that his or her 
specific disease was caused by exposure to the chemical at issue. 
If, on the other hand, a reasonably convincing case could be made 
                                                          
1 FEDERAL JUDICIAL CENTER, REFERENCE MANUAL ON SCIENTIFIC 
EVIDENCE 383, 547 n. 278, 547-48 n. 280, 548 n. 282 (2d ed. 2000) available at 
http://www.fjc.gov/public/pdf.nsf/lookup/sciman00.pdf/$file/sciman00.pdf. 
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that general causation has been established, the scientific 
evaluation can move to the question of plaintiff-specific causation: 
did the plaintiff incur sufficient exposure to the chemical at issue 
to allow the conclusion that the plaintiff’s specific medical 
condition was more likely than not caused by that exposure?2 For 
example, an individual who was diagnosed with acute 
myelogeneous leukemia and had experienced exposure to benzene 
would have a compelling case for general causation. But if that 
individual’s exposure were very low, it may not be possible for an 
expert to show convincingly that specific causation can be 
established. Benzene is not the only cause of this type of leukemia 
and a demonstration that some undefined level of benzene 
exposure had occurred is a far from adequate basis for establishing 
specific causation.3 
Even if general and specific causation have been established, 
there may remain other factors in the plaintiff’s life that are even 
likelier explanations for his or her condition; the subject of 
“alternative causation” is also outside the scope of this paper, but 
will be briefly discussed in a later section. General and specific 
causation are thus the topics to be covered. 
This paper shall begin in Part I with some general background 
on chemical toxicity and the scientific methods used to identify the 
toxic properties of specific chemicals. The use of toxicological 
information by public health and regulatory authorities for 
purposes of public health protection merits discussion because 
there are certain parallels between the types of questions these 
authorities pursue and those arising in a tort setting. In this regard, 
the question of the utility of experimental data on toxicity, 
typically derived from studies in laboratory animals, requires close 
                                                          
2 In some cases, a plaintiff may have been a member of a specific 
population exposed to the chemical at issue and the subject of some type of 
direct epidemiology study. Evaluating the likelihood that such a study could 
provide evidence of both general and specific causation in the plaintiff requires 
methods that are not discussed in this paper. This paper focuses on the far more 
typical situation in which such studies have not been conducted. 
3 In fact, because of its presence in gasoline, human exposure to some level 
of benzene is virtually ubiquitous. 
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scrutiny. Part II addresses how public health and regulatory 
scientists evaluate the potentially adverse health consequences of 
chemical exposures within a framework called risk assessment. 
That same framework is useful for evaluating disease causation in 
individuals, but we shall see that some of the types of scientific 
evidence used commonly in the regulatory context may not be 
appropriate for evaluating causation in individuals. Following that 
discussion, in Part III, the evaluative methods used to understand 
general and specific causation are outlined. This paper concludes 
in Part IV with a discussion of the attendant limitations of general 
and specific causation. 
I. CHEMICAL TOXICITY AND SCIENTIFIC METHODS USED TO 
IDENTIFY TOXIC PROPERTIES OF SPECIFIC CHEMICALS 
Scientists undertaking toxicological risk assessments in the 
regulatory setting commonly disagree on the interpretation of 
specific study results, but they nevertheless work within a common 
understanding of the types of scientific evidence appropriate for 
such assessments. This common understanding has resulted from 
half a century of scientific dialogue, much of it guided by many 
expert reports on this topic issued by various arms of The National 
Academies since the early 1980’s.4 No such history of scientific 
discourse has informed the risk assessment process as it relates to 
disease causation in individuals, and it is difficult to discern 
anything remotely like a scientific consensus on how different 
types of scientific evidence should be used in such assessments. 
What is presented here might represent the thinking of most 
                                                          
4 The National Academies has issued hundreds of reports on specific issues 
of chemical toxicity. For a recent example, see NAT’L RESEARCH COUNCIL, 
HEALTH IMPLICATIONS OF PERCHLORATE INGESTION (2005), available at 
http://www.nap.edu/books/030904894X/html/. For a broad view of approaches 
to risk assessment, see COMM’N OF LIFE SCI., NAT’L RESEARCH COUNCIL, SCI. 
AND JUDGMENT IN RISK ASSESSMENT (1994) [hereinafter SCIENCE AND 
JUDGMENT], available at http://www.nap.edu/books/030904894X/html/; 
COMM’N OF LIFE SCI., NAT’L RESEARCH COUNCIL, THE NAT’L RES. COUNCIL’S 
COMMITTEE ON TOXICOLOGY: THE FIRST 50 YEARS (1997), available at 
http://www.nap.edu/books/ 030904894X/html/. 
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scientists, but no scientist writing on this topic would claim that it 
represents a consensus, or that there are no alternative approaches 
that might have utility. If an appropriate government sponsor could 
be found, the subject of scientific evidence and disease causation 
in individuals could surely benefit from a study by The National 
Academies. 
A. Chemical Toxicity 
All chemical substances, whether of natural or synthetic origin, 
can cause toxicity—some type of harm to the structure or 
functioning of the body—under some conditions of exposure; thus, 
as a technical matter, all chemicals can be said to be toxic.5 The 
types of adverse health effects and the conditions of exposure 
necessary to cause those effects vary widely among chemicals.6 
The conditions under which we are exposed to most of the millions 
of natural and synthetic chemicals that surround us are such that 
their toxic properties are never expressed, but we recognize 
perhaps hundreds of chemicals that do present some risk of toxicity 
and that we are exposed to many more chemicals that have yet to 
be investigated for their risk potential. Regulatory agencies, such 
as the Environmental Protection Agency, the Occupational Safety 
and Health Administration, and the Food and Drug Administration, 
develop, for various administrative purposes, lists of hazardous 
(toxic) substances.7 Chemicals so listed are usually those with 
                                                          
5 See PRINCIPLES AND METHODS OF TOXICOLOGY (A. Wallace Hayes ed., 
4th ed. 2001); JOHN TIMBRELL, INTRODUCTION TO TOXICOLOGY (3d ed. 2001). 
The standard might be CASARETT AND DOULL’S TOXICOLOGY: THE BASIC 
SCIENCE OF POISONS (Curtis Klaassen ed., 6th ed. 2001) [hereinafter CASARETT 
AND DOULL’S]. The general background provided in this section is also 
provided, in extended form, in JOSEPH RODRICKS, CALCULATED RISKS: 
UNDERSTANDING THE TOXICITY AND HUMAN HEALTH RISKS OF CHEMICALS IN 
OUR ENVIRONMENT (1992). 
6 Dose, duration, timing, route of entry into the body, etc. David L. Eaton 
& Curtis D. Klaassen, Principles of Toxicology, in CASARETT AND DOULL’S, 
supra note 5, at 11, 13-14, 17-26. 
7 Data on the toxic properties of most of the chemicals regulated by the 
EPA can be found at http://www.epa.gov/iris/subst/index.html. OSHA’s listing 
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well-recognized toxic properties and to which large numbers of 
people are or could be exposed. It should be recognized that many 
substances not listed as hazardous may well pose health risks under 
some conditions and that not all listed substances will pose health 
risks under all conditions of exposure.8 This topic will be 
developed more fully in the later section on risk assessment. 
Toxicity expresses itself in many different ways. Some 
chemicals cause harm to the respiratory or nervous systems, while 
others can harm the liver or the kidneys. Some chemicals may 
cause harm to several different organs or systems of the body, 
although the conditions of exposure necessary to cause harm in 
different organs or systems often vary even for a specific chemical. 
Many chemicals, which we label carcinogens, can cause malignant 
tumors to appear in different cells of the body. There are chemicals 
that can adversely affect immune or endocrine functions, or that 
can interfere with reproductive processes. The developing embryo 
or fetus is a target for some chemicals. In recent years much 
attention is being devoted to the ways chemicals such as a lead and 
methyl mercury, found in fish, can put children at risk of impaired 
cognitive development or cause behavioral abnormalities. There is 
an immense body of scientific literature concerning the adverse 
effects of chemical exposures and the conditions under which they 
occur, and it is now growing at a relatively rapid pace.9 Moreover, 
                                                          
of regulated workplace chemicals can be found at http://www.osha-
slc.gov/SLTC/pel/index.html. The FDA has several centers that regulate 
different categories of chemicals. See U.S. FOOD AND DRUG ADMIN., NAT’L 
CTR. FOR TOXICOLOGY RESEARCH Home Page, http://www.fda.gov/nctr/ 
index.html. A comprehensive, integrated database on chemical toxicity can be 
found at http://risk.lsd.ornl.gov/tox/tox_values.shtml. The Agency for Toxic 
Substances and Disease Registry (ATSDR) provides comprehensive toxicity 
reviews on many important chemicals. See ATSDR, TOXICOLOGICAL PROFILE 
INFO. SHEET, http://www.atsdr.cdc.gov/toxpro2.html. 
8 See Eaton & Klaassen, supra note 6, at 13-16. See also SCIENCE AND 
JUDGMENT, supra note 4, at 25-42. 
9 The National Toxicology Program is a multi-agency activity of the 
Department of Health and Human Services and is both an important toxicology 
and epidemiology research center and a source of information on the many 
growing areas of research and testing of chemicals. See generally NATIONAL 
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many basic scientists have turned their attention to the difficult 
scientific tasks of understanding the fine details of the chemical 
and biological processes that take place after a chemical enters the 
body and to the point at which its toxicity becomes detectable; 
much progress is being made in understanding “toxic 
mechanisms.”10 
Although we are exposed to many thousands of chemicals, 
including a large share of natural origin, present mostly as the non-
nutritive constituents of food, it appears that we are not harmed by 
most of these exposures.11 The absence of harm is probably 
attributable to the fact that chemical toxicity does not express itself 
under all conditions. Toxic responses are a function of the 
magnitude of the dose12 and it is established with high certainty 
that toxic responses do not appear until a so-called threshold dose 
is exceeded;13 they increase in incidence, severity, or both, as the 
dose increases above the threshold, but we are protected from harm 
                                                          
TOXICOLOGY PROGRAM, http://ntp-server.niehs.nih.gov. 
10 See generally Harvey Clewell, Use of Mode of Action in Risk 
Assessment: Past, Present, and Future, 42 REG. TOXICOLOGY AND 
PHARMACOLOGY 3-14 (2005). 
11 “Appears” is used here because it is extraordinarily difficult to acquire 
knowledge about such potential risks. There is no way to document this 
assertion because there has been no systematic study of most of the many 
thousands of natural and synthetic chemicals to which all of us are exposed 
daily, over our full lifetimes. But most human disease is attributable to the major 
life-style factors—smoking, nutritional practices, alcohol abuse, infectious 
diseases, lack of exercise—so it seems reasonable to conclude that we are able 
to tolerate most chemical exposures without adverse consequence. See generally 
WORLD HEALTH ORG., THE WORLD HEALTH REPORT: REDUCING RISKS, 
PROMOTING HEALTHY LIFE 82 (2002) (summarizing the major sources of human 
morbidity and mortality). 
12 See Eaton & Klaassen, supra note 6, at 17-24 (explaining that dose refers 
to the amount of chemical taken that actually enters the body usually per unit of 
time as a result of exposure). 
13 Id. at 19. See also INT’L PROGRAMME ON CHEM. SAFETY, PRINCIPLES 
FOR THE ASSESSMENT OF RISKS TO HUMAN HEALTH FROM EXPOSURE TO 
CHEMICALS, ENVTL. HEALTH CRITERIA 210, at 4.3.1, available at 
http://www.inchem.org/documents/ehc/ehc/ehc210.htm [hereinafter INT’L 
PROGRAMME]. 
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if the threshold dose is not exceeded. This “threshold hypothesis” 
is well-documented, although it is not possible to claim the 
hypothesis holds for every chemical or type of toxicity. In fact, as 
shall be seen below, there is evidence it may be incorrect for 
certain types of carcinogens.14 The issues of thresholds and dose-
response relationships are critical in the evaluation of specific 
causation.15 
B. Identifying Toxic Properties 
It is, of course, unethical to test chemicals for toxicity in 
humans. Pharmaceutical substances are delivered to human 
subjects in controlled clinical trials, but only after there is 
sufficient experimental animal data to provide high assurance that 
the toxic properties associated with every drug will not be 
expressed at the doses used in a trial. Adverse side effects may 
occur during a trial, occasionally with a frequency or severity that 
may require the trial to be halted. Clinical trials are conducted 
under a set of internationally recognized ethical codes, which 
recognize the important health benefits drugs confer.16 Such 
controlled trials are clearly not appropriate for studying toxicity. 
                                                          
14 Compare Steve E. Hrudey & Daniel Krewski, Is There a Safe Level of 
Exposure to a Carcinogen?, 29 ENVTL. SCI. & TECH. 370A (1995) 
(summarizing the evidence on both sides of the “no-threshold” debate on 
carcinogens), with Samuel M. Cohen, Human Carcinogenic Risk Evaluation: An 
Alternative Approach to the Two-Year Rodent Bioassay, 80 TOXICOLOGICAL 
SCI. 225 (2004) (providing several examples of threshold mechanisms for 
carcinogens). See also Elaine M. Faustman & Gilbert S. Omenn, Risk 
Assessment, in CASARETT AND DOULL’S, supra note 5, at 83, 92-99. 
15 See sources cited supra note 5 (explaining that exposure refers to the 
contact between an individual and the environmental medium in which a 
chemical is present; dose refers to the amount of chemical that actually enters 
the body usually per unit of time as a result of exposure; dose-response refers to 
the quantitative relationship between dose and toxic response). See also INT’L 
PROGRAMME, supra note 13, at 4.1 and 5.2 (respectively explaining dose-
response, exposure and dose). 
16 WORLD MED. ASS’N, DECLARATION OF HELSINKI: ETHICAL PRINCIPLES 
FOR MED. RESEARCH INVOLVING HUMAN SUBJECTS (1964) (amended 2004), 
available at http://www.wma.net/e/policy/pdf/17c.pdf. 
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Much can be learned about chemical toxicity by careful 
observation of groups of individuals who experience common 
exposures, usually incident to their occupations.17 Other discrete, 
non-occupational cohorts may also be subject to such observational 
studies. 
Epidemiologists have developed several investigative methods 
to conduct such studies and can design them in ways to build-in 
some type of control group; however, none of these 
epidemiological studies (cohort, case-control) are ever “controlled” 
in the same way a laboratory experiment or clinical trial is 
controlled.18 Only in well-controlled experiments can cause-effect 
relationships be established with reliability. Individual 
epidemiology studies are at best designed to identify whether a 
statistical association exists between a chemical exposure and a 
specific disease or toxic injury outcome – that is, to determine 
whether one event, such as chemical exposure to a chemical, 
occurs together with a second event, such as a specific disease or 
toxic injury, more frequently than would be expected without such 
                                                          
17 These types of exposures are typically greater than those occurring in the 
general population. Petroleum refinery workers are exposed to benzene in the 
range of 0.5 to 1 ppm. The general population averages about 0.01 ppm. This 
type of difference is typical for hundreds of industrial chemicals. There are 
many reasons for these differences, but the major one is occupational situations 
involving direct contact with and handling of chemicals. Emissions of these 
same chemicals to the environment (air, water, food) results in significant 
dilution. Alon Rosenthal, George M. Gray & John D. Graham, Legislating 
Acceptable Cancer Risk from Exposure to Toxic Chemicals, 19 ECOL. L.Q. 269, 
280 (1992) (discussing the need to extrapolate from high dose occupational 
exposures to low levels of environmental exposure). 
18 Clinical trials are inherently not as well-controlled as experiments 
involving animals, where environments, diet, and genetic characteristics in test 
and control groups are virtually identical except for the presence of the chemical 
under test. Brian L. Strom, Study Designs Available for Pharmacoepidemiology 
Studies, in PHARMACOEPIDEMIOLOGY 17, 17-29 (Brian L. Strom ed., 3d ed. 
2000). See also LEON GORDIS, EPIDEMIOLOGY chs. 7, 12 (2d ed. 2000) (on 
randomized trials and comparing cohort and case-controlled studies); Nelson H. 
Wilson et al., Short-Term, Subchronic, and Chronic Toxicology Studies, in 
PRINCIPLES AND METHODS OF TOXICOLOGY, supra note 5, at 917, 932, 936-38 
(discussing well-controlled animal studies). 
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chemical exposure. Other factors that may bias or confound any 
observed association also need to be identified and, if possible, 
eliminated as alternative explanations for the association.19 
Although epidemiological studies are highly relevant to 
identifying the toxic properties of chemicals that are of concern for 
our species, no single study is sufficient to establish causation. 
Epidemiologists await a body of evidence from several studies, 
ideally involving different study methods, investigators, and 
population groups. Consistency among study outcomes and clear 
evidence that risk increases with increasing exposure  (dose), 
strong statistical associations, and supporting experimental data, 
are considered the necessary hallmarks of true causality; 
nonetheless, causality can never be determined with complete 
certainty.20 Expert groups, such as those convened by bodies such 
as the International Agency for Research on Cancer (IARC), a unit 
of the World Health Organization, or the federal National 
Toxicology Program, periodically review evidence and typically 
assign weights to it.21 The IARC, for example, describes the 
                                                          
19 Michael D. Green et al., Reference Guide on Epidemiology, in 
REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, supra note 1, at 333. 
20 GORDIS, supra note 18, at 184-218 (providing a thorough discussion of 
approaches to evaluating causality). See also sources cited infra note 21 
(referencing reports on causality of carcinogens from the International Agency 
for Research on Cancer, Environmental Protection Agency, and U.S. 
Department of Health and Human Services). 
21 The International Agency for Research on Cancer (IARC), a division of 
the World Health Organization (WHO), issues expert reports on causes of 
cancer. Reports on occupational and other sources of carcinogens each contain 
descriptions of how epidemiological and experimental evidence is evaluated in 
each instance to reach conclusions regarding causation. See IARC, 
http://www.iarc.fr (last visited Oct. 27, 2005). See also RISK ASSESSMENT 
FORUM, ENVTL. PROTECTION AGENCY, GUIDELINES FOR CARCINOGEN RISK 
ASSESSMENT (1999) [hereinafter RISK ASSESSMENT FORUM], available at 
http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=439797 
(providing EPA’s framework for assessing possible cancer risks); U.S. DEP’T OF 
HEALTH & HUMAN SERV., NAT’L TOXICOLOGY PROGRAM, REPORT ON 
CARCINOGENS (11th ed. 2005), available at http://ntp-server.niehs.nih.gov/ 
index.cfm?objectid=32BA9724-F1F6-975E-7FCE50709 CB4C932 (discussing 
agents, substances, mixtures, and exposure circumstances that may pose a 
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evidence on specific substances, or sometimes mixtures of 
chemicals or even certain occupational settings in which the 
specific causative chemical(s) has not been identified, as sufficient 
when causal criteria are judged to have been met by the agency’s 
expert panels.22 The IARC’s expert panels also describe evidence 
on other substances as sufficient to establish an association but 
insufficient to establish causation, or as only insufficient.23 At the 
present time, the IARC lists 95 substances, mixtures, or 
occupations as causally related to cancer, based on epidemiological 
data.24 It can be said that any substance so listed qualifies as a 
                                                          
hazard to human health by virtue of their carcinogenicity). 
22 See, e.g., 77 IARC, WHO, MONOGRAPHS ON THE EVALUATION OF 
CARCINOGENIC RISKS TO HUMANS: SOME INDUSTRIAL CHEMICALS (2000) 
[hereinafter SOME INDUSTRIAL CHEMICALS], available at http:www-
cie.iarc.fr/htdocs/indexes/vol77index.html (describing studies of sixteen specific 
chemicals where there was insufficient evidence to establish causation in 
humans). But see 62 IARC, WHO, MONOGRAPHS ON THE EVALUATION OF 
CARCINOGENIC RISKS TO HUMANS: WOOD DUST FORMALDEHYDE 35 (1998), 
available at http://www-cie.iarc.fr/htdocs/monographs/vol62/wood.html 
(finding sufficient evidence of cancer causation in humans in case of wood dust, 
based on a large body of case-control and cohort studies). 
23 IARC, WHO, MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC 
RISKS TO HUMANS: PREAMBLE (1999), available at http://www-cie.iarc.fr/ 
monoeval/eval.html (listing categories used to classify the degree of evidence 
related to carcinogenicity in specific organs or tissues). Evidence regarding 
specific substances may fall into these categories if some, but not all, of the 
criteria described in the opening sentences of this paragraph are met. Expert 
committees provide descriptions of the available evidence and why it may fail to 
meet criteria for causation. See also SOME INDUSTRIAL CHEMICALS, supra note 
22 (listing IARC descriptions of the evidence for any of the 16 chemicals 
evaluated and reasons why causation criteria were not met). 
24 In all, IARC expert panels have evaluated 900 individual substances, 
chemical mixtures, and occupational exposure situations. IARC, WHO, LISTS OF 
IARC EVALUATIONS (2004), available at http://www-cie.iarc.fr/monoeval/ 
grlist.html. The evidence that each substance, mixture, and occupational 
exposure causes cancer is rated on a scale of 1-4; 1 is for agents that definitely 
cause cancer and 2A is for those that probably cause cancer. Id. Categories 1 and 
2A may be sufficient to  establish general causation as a matter of law. See 
REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, supra note 1 & accompanying 
text. Roughly 20 percent of evaluated substances, mixtures, and occupational 
exposures fall into category 1 or 2A. IARC, WHO, OVERALL EVALUATIONS OF 
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general cause of the specific type(s) of cancer for which it is listed, 
although experts can be found who will have reasons to question 
the IARC’s listings. In any event, there is no stronger evidence for 
general causation of chemical toxicity than that obtained from a 
body of epidemiological evidence meeting causation criteria.25 
Exceptions to this rule may apply in the case of pharmaceutical or 
other medical products, because controlled clinical trials are more 
readily useful for establishing causation (or its absence) than are 
epidemiological studies.26 
Epidemiological studies cannot be conducted until after 
chemical products are introduced into commerce and for some 
diseases, such as cancers with latency periods of many years or 
decades, much time must pass before results can be collected and 
evaluated. For these and other reasons, toxicologists have 
developed and continue to improve various methods for collecting 
toxicity data in laboratory animals. Toxicology studies in animals 
began to be used in the 1930’s and for a time focused on relatively 
                                                          
CARCINOGENICITY TO HUMANS (2004), http://www-cie.iarc.fr/monoeval/ 
crthall.html. 
25 Differential diagnoses are frequently used by examining physicians to 
identify the cause of a medical condition in individual patients. In most cases, 
the physician relies upon established knowledge regarding the various causes of 
specific conditions. In some cases, a physician may think he or she has 
identified a new (previously unreported) cause for a disease or injury and may 
seek publication in medical journals of the findings. Such “case reports,” 
especially if a series of similar reports appears over time, can be of high value in 
generating hypotheses about causal relations. Such hypotheses can then be 
studied epidemiologically, but establishing causal relationships based only on 
such reports is highly problematic because in the absence of controls, it is nearly 
impossible to determine whether the condition would also have occurred in the 
individual patient in the absence of exposure to the suspect chemical. See 
GORDIS, supra note 18 (describing why such case reports are of highly limited 
utility in establishing causation); Judith K. Jones, Determining Causation from 
Case Reports, in PHARMACOEPIDEMIOLOGY, supra note 18, at 525-38 
(discussing the limitations and the potential value of such reports). See also 
STROM, supra note 18, at 22. 
26 See STROM, supra note 18, at 26-27 (“Randomized clinical trials are ‘the 
gold standard’ by which other designs must be judged.”). 
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intense exposures of limited duration.27 Nowadays, studies 
typically involve several species, extend over the animals’ 
lifetimes, and involve an examination of reproductive and 
developmental effects. Every manifestation of a chemical’s 
toxicity can be uncovered using animals through detailed tissue 
pathology (this is not even remotely possible in human studies). As 
noted earlier, because such studies are strictly controlled, they can 
be used to identify cause-effect relationships with greater 
reliability. 
C. Utility of Animal Data 
Rats, mice, dogs, and pigs are commonly used in toxicology 
experiments and, although there is extensive work underway to 
identify test systems that will not require the use of whole animals, 
it is likely such experiments will continue to be carried out, 
because of the intense interest in the United States and in the 
European Union (the EU) to acquire more complete toxicology 
data on ever greater numbers of chemicals.28 The primary uses of 
such data are to identify the toxic properties of chemicals, the 
threshold doses for toxicity, and, through the use of a method 
termed ‘risk assessment,’ exposure levels (doses) that will not pose 
toxic risks to human populations. 
While regulatory agencies prefer to use epidemiological 
evidence to identify protective levels for human populations, they 
will not hesitate to use animal toxicology data when human data 
are limited or altogether lacking.29 There is substantial scientific 
                                                          
27 Joseph F. Borzelleca, The Art, the Science, and the Seduction of 
Toxicology: An Evolutionary Development, in PRINCIPLES AND METHODS OF 
TOXICOLOGY, supra note 5, at 1-22. 
28 The regulators of the European Union (the EU) are in the process of 
developing a Registration, Evaluation, and Assessment of Chemicals program 
(REACH).  At present, it targets thousands of chemicals for testing. Whether 
this ambitious goal is retained in the program’s final form is unknown. See 
generally REACH, at http://europa.eu.int/comm/environment/chemicals/ 
reach.htm. 
29 See ENVTL. PROTECTION AGENCY [hereinafter EPA], INTEGRATED RISK 
INFORMATION SYSTEM [hereinafter IRIS], available at http://www.epa.gov/ 
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basis for this regulatory policy.30 
First, factors that influence toxicity are generally similar across 
mammalian species, as are cells, cellular components, and 
extracellular environments.31 Thus, biological factors that 
influence a chemical’s behavior in the body and its interaction with 
the specific sites where it causes damage are generally similar 
across all mammalian species. These basic biological similarities 
suggest that chemicals that produce specific forms of toxicity in 
animals will also do so in humans, given a sufficient dose; 
however, similar does not equate to identical.32 
While there appears to be a concordance between the types of 
toxic responses seen in animals and that observed in humans for 
those cases in which both human and animal data are available, 
often for unexplained reasons the specific manifestations of 
toxicity (e.g., type of cancer) differ across species.33 Thus, while 
                                                          
iris/subst/index.html. The EPA has evaluated the toxic properties of hundreds of 
chemicals and derived toxicity risk factors based on either human or animal 
evidence. Animal evidence is the primary source for these risk factors, because 
human evidence is either lacking or is inadequate. Good examples of chemicals 
listed in the IRIS database that are regulated based on animal data are 
acrylamide, acrylonitrile, and carbon disulfide. See EPA, OFFICE OF THE SCI. 
ADVISOR, RISK ASSESSMENT PRINCIPLES & PRACTICES 76-77 (2004) [hereinafter 
EPA, RISK ASSESSMENT PRINCIPLES & PRACTICES], available at 
http://www.epa.gov/osainter/pdfs/ratf-final.pdf (providing examples of four 
substances for which some human data on toxicity were available but were not 
used for IRIS toxicity evaluations. In each case, the agency used animal data to 
derive toxicity factors). 
30 The clearest exposition of the basis for this regulatory policy can be 
found in a volume published by a committee of the National Research Council. 
See generally, COMM. ON THE INSTITUTIONAL MEANS FOR ASSESSMENT OF 
RISKS TO PUB. HEALTH, NAT’L RESEARCH COUNCIL, RISK ASSESSMENT IN THE 
FED. GOV’T: MANAGING THE PROCESS (1983) [hereinafter RISK ASSESSMENT IN 
THE FEDERAL GOVERNMENT] (establishing the risk assessment framework that is 
used by regulatory and public health institutions throughout the world). 
31 I.e., Anatomy, physiology, and biochemical processes. See RISK 
ASSESSMENT PRINCIPLES & PRACTICES, supra note 29, at § 4. 
32 See RISK ASSESSMENT IN THE FEDERAL GOVERNMENT, supra note 30. 
33 Harry Olson et al., Concordance of the Toxicity of Pharmaceuticals in 
Humans and Animals, 32 REGULATORY TOXICOLOGY AND PHARMACOLOGY, 56, 
56-67 (2000) (discussing a careful study on this issue and also providing 
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regulators may be on solid ground to conclude that an animal 
carcinogen may be a human carcinogen, they would be on much 
shakier ground if they were to conclude that the specific type of 
cancer (or other toxicity) that occurs in animals is also likely to 
occur in sufficiently exposed humans.34 
For regulatory purposesthat is, for purposes of developing 
standards to limit exposures to ensure protection of human 
populationsit is not essential to know which specific type of 
cancer or other disease is caused by a chemical. For public health 
protection, that particular type of scientific uncertainty is not 
important, or so the regulators have traditionally held.35 
Another factor limiting the use of animal data for drawing 
strong inferences about humans concerns the doses necessary to 
cause adverse effects. Here, animal-human differences seem to be 
significant, and the magnitudes of those differences are generally 
unpredictable. For example, even if a chemical established as 
causing liver injury in rodents is assumed to be a liver toxicant in 
humans, identifying the human dose necessary to cause that 
toxicity is not possible without imposing incompletely tested 
assumptions. 
Thus, while animal data are routinely used for public health 
protection, they are of limited utility for establishing general 
causation in humans. They may be used to buttress findings from 
human studies, but when no human data are available, it would 
seem to stretch scientific understanding beyond its limits to 
conclude that specific health effects found in animals will with a 
reasonable degree of scientific certainty be expected to occur in 
                                                          
examples). See also RODRICKS, supra note 5, at 137 tbl. 7 (citing animal-human 
differences in cancer-types related to the same chemical). 
34 See 2 INSTITUTE OF MEDICINE OF THE NAT’L ACADEMIES, BOARD ON 
HEALTH PROMOTION & DISEASE PREVENTION, GULF WAR AND HEALTH: 
INSECTICIDES AND SOLVENTS 98-349 (2003) (providing an extended discussion 
on this issue and evaluating the general disease causation for chemical 
substances to which U.S. military personnel may have been exposed during the 
Gulf War). 
35 See RISK ASSESSMENT FORUM, supra note 21.  The EPA recognizes that 
animal cancer data may not predict specific cancer types in humans, but 
frequently uses such data for human cancer risk assessment. Id. § 2.2.2.1. 
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sufficiently exposed humans; and identifying sufficient exposure 
from the animal data is even more problematic.36 
II. REGULATORY RISK ASSESSMENTS 
“Risk assessment” is a framework within which data regarding 
the adverse health effects caused by chemicals derived from 
epidemiological and experimental studies, and information 
regarding the conditions under which human populations are or 
could be exposed to those chemicals, are integrated to yield a 
description, usually quantitative in nature, of the likelihood that 
those adverse effects will occur in the exposed populations.37 That 
likelihood of adverse effects occurring in the exposed populations 
is called a risk.38 Risk assessment serves to bridge the gap between 
research and the needs of so-called risk managers; the latter are 
typically regulatory and public health decision-makers. Research 
findings and other forms of data arise from diverse sources, have 
varying degrees of utility and quality, and are not infrequently 
contradictory; risk assessors have the difficult task of making sense 
of such data and using the results to present risk managers with as 
coherent a description of risk as the underlying science allows. 
Risk assessments are typically directed at an existing exposure 
situation, such as the risks incurred by populations residing in the 
vicinity of a manufacturing or hazardous waste facility, or at the 
exposure situation expected if certain regulatory actions are 
taken.39 Those actions are usually taken if the existing risks are 
judged excessive; risk assessors’ goal is to reduce risks to 
acceptably low levels, the technical definition of safe levels.40 
                                                          
36 See REFERENCE MANUAL ON SCIENTIFIC EVIDENCE, supra note 1. 
37 See RISK ASSESSMENT IN THE FEDERAL GOVERNMENT, supra note 30, at 
18. 
38 Id. 
39 EPA, RISK ASSESSMENT PRINCIPLES & PRACTICE, supra note 29, at 99-
112 (providing  a thorough description of how the agency approaches all the 
human exposure circumstances associated with a typical (and complex) 
hazardous waste site, as the focus of its risk assessment process). 
40 “Safe” is often taken to mean the complete absence of a risk. As a 
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Often, risk assessors evaluate the epidemiology, toxicology, and 
dose-response information for purposes of establishing a safe 
exposure level for a specific chemical.41 Those safe levels are then 
used to establish standards for the chemical that apply to specific 
environmental mediaallowable limits on the concentrations of 
the chemical in water, air, food, or soil, or in workplace 
environments. Measured concentrations of chemicals in these 
media can be compared with the standards to determine whether a 
risk exists. 
The foundations for current approaches to risk assessment were 
set forth in a study produced in 1983 by the National Academy of 
Sciences.42 The study authors noted that, given the current state of 
scientific understanding, which has improved in the past 20 years 
but has not overcome the basic problems in risk assessment, and 
also given the compelling need to conduct risk assessments for 
public health protection, regulators would be required to invoke 
certain assumptions in the conduct of risk assessments.43 These 
assumptions address the limits of our knowledge and may not have 
firm scientific support, but risk assessments cannot be completed 
without them. 
In the context of regulatory risk assessment three such issues 
stand out: 1) the need to extrapolate from epidemiological and 
                                                          
technical matter such situations—which require proof of a negative condition—
cannot be demonstrated to exist. Completely safe conditions may actually exist, 
but there is no scientifically rigorous method for identifying them. RODRICKS, 
supra note 5, at 204-11 (providing a discussion of the relationship between 
safety and risk). The toxicity risk factors (“Reference Doses”) derived and 
presented by the EPA in its IRIS database are used as maximum “safe” exposure 
levels for chemicals. See IRIS, supra note 29. The Reference Dose is, however, 
not characterized by the agency as safe, but rather as a dose at which the 
probability of an adverse toxic response is negligibly small. See Barbara D. 
Beck et al.,  The Use of Toxicology in the Regulatory Process, in  PRINCIPLES 
AND METHODS OF TOXICOLOGY, supra note 5, at 23, 47. 
41 Beck et al., supra note 40, at 23.  The entire chapter is devoted to the 
methods used to establish the safe (negligible risk) doses set forth in EPA’s IRIS 
database. Nearly identical methods are used by other agencies. See also sources 
cited supra note 13. 
42 RISK ASSESSMENT IN THE FEDERAL GOVERNMENT, supra note 30. 
43 Id. at 51-85. See also id. at 7 (Recommendation B). 
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experimental results obtained at doses substantially greater than 
those incurred by populations that are the typical subjects of risk 
assessments; 2) the need to extrapolate from experimental results 
to human beings; and 3) the need to deal with the known potential 
for variability in response to chemical exposures among a large, 
diverse human population. Scientific knowledge in these areas is 
limited. Other such limitations exist regarding the nature and 
extent of human exposures. Regulators have responded to the 
National Academy of Sciences study by describing the usual 
default assumptions to be used, while noting that in specific cases 
scientific knowledge may exist to permit departures from those 
assumptions.44 Risk assessment is, thus, not a scientific activity in 
the usual sense; moreover, in many cases, testing the results of a 
risk assessment by additional epidemiological investigations is 
beyond current scientific capabilities.45 In the absence of any 
attempt to assess risks, it is not possible to have an understanding 
of whether public health is adequately protected, or whether new 
products can be safely introduced into commerce. 
The approach to chemical risk assessment used by regulatory 
authorities is designed to evaluate risks to what might be called 
“generic” individuals.46 It is recognized that responses to chemical 
                                                          
44 See RISK ASSESSMENT FORUM, supra note 21. 
45 Regulatory and public health policies attempt to ensure that risks are 
controlled at levels substantially below those that can be identified using the best 
available epidemiology tools. Arhtur C. Upton, Perspectives on Individual and 
Community Risks, in  ENVIRONMENTAL TOXICANTS 905-11 (Morton Lippman 
ed.,  2nd ed. 2000). Public health policies are limited to detecting relatively large 
risks. Some scientists argue that precious resources are wasted in regulating 
“non-detectable risks” (i.e., those that are estimated using the regulatory risk 
assessment approach), but regulatory and public health officials have generally 
interpreted our laws as requiring the cautious approach to public health 
protection. See Gary Taubes & Charles Mann, Epidemiology Faces its Limits, 
269 SCIENCE 164, 164-69 (1995). 
46 By use of the term generic, I mean hypothetical individuals within 
populations that are the subjects of risk assessments that are assumed to be 
equally sensitive to the hazardous effects of a chemical. “Generic” is my short-
hand. See SCIENCE AND JUDGMENT, supra note 4, ch. 10 (discussing the issue of 
variability at length). Inspection of the process used by EPA (IRIS data base) 
reveals how the risk assessment process is designed to focus on the high-risk 
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exposures are variable within populations, and regulators target 
those generic individuals who are at the high end of sensitivity. If 
standards are developed to protect those individuals, then all others 
in the population, who are less sensitive, can be assumed to be 
protected. Moreover, regulators estimate population exposures by 
making assumptions that target those similarly generic individuals 
at the high end of the range of population exposures.47 
It is not possible to determine, except in unusual 
circumstances, which actual individuals in a population are at the 
high end of sensitivity and also at the high end of exposure. In this 
sense it can be said that regulatory risk assessments apply to 
generic, as opposed to actual individuals. This fact alone limits 
significantly the applicability of regulatory risk assessments and 
the various standards derived from them to the evaluation of 
general and specific causation in actual individuals. Further, for at 
least those regulatory risk assessments and standards that are based 
primarily on experimental animal data, the relevance to individual 
causation analysis is highly dubious.48 
A final point regarding regulatory risk assessments is that the 
so-called safe levels are derived from the epidemiological or 
experimental toxicity data by the use of assumptions49 that have 
the effect of placing those levels at a very small fraction of the 
observed threshold levels.50 The reasons for this effect are 
                                                          
(most sensitive) responders in the population. See IRIS, supra note 29. 
47 See SCIENCE AND JUDGMENT, supra note 4, 43-55 (in particular, note the 
section entitled Maximally Exposed Individual at 46). 
48 See discussion supra Part I.C. 
49 Sometimes expressed in the form of certain mathematical models. It is 
common, for example, to use what is called a linear, no-threshold model to 
estimate low dose cancer risks, based on data obtained at high doses.  See 
Faustman & Omenn, supra note 14, at 75-88 (describing such a model); Beck et 
al., supra note 40. 
50 Regulators assume, in the absence of evidence to the contrary, that 
carcinogenic chemicals act through mechanisms that disobey the general 
“threshold” rule for toxicity. This does not translate to the sometimes expressed 
view that any level of carcinogen exposure can cause cancer. See sources cited 
supra note 14. See also Upton, supra note 45 (describing regulated risk levels). 
Instead, it means only that any exposures to carcinogens will increase cancer 
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complex, and will not be described here, but they are related to 
general knowledge regarding the behavior of chemicals when they 
are present at toxic levels, and the lack of specific knowledge 
pertaining to the magnitude of human variability, animal-to-human 
and high-to-low dose extrapolation, and many other aspects of a 
risk assessment. Because of this and because the regulatory 
standards are designed to protect the generic, highest risk 
individuals, it is likely that actual individuals in a population 
exposed at levels less than those standards are not at risk. 
Exposures at levels in excess of regulatory standards will not 
necessarily lead to toxic injury or disease; knowledge that such 
exposures have occurred is, by itself, completely inadequate to 
establish disease causation in individuals. This is not an expression 
of lack of concern for situations in which regulatory standards are 
exceeded. It is rather a statement regarding the lack of utility of 
this kind of information for assessing injury causation in actual 
individuals. 
III. GENERAL AND SPECIFIC CAUSATION IN ACTUAL INDIVIDUALS 
There are models of evaluation, similar conceptually but not in 
actual execution to the regulatory risk assessment model, that are 
useful for evaluating general and specific causation in actual 
individuals. Assuming that a plaintiff has been properly diagnosed 
as having a specific disease or injury, and assuming that the legal 
standard for establishing causation is the more likely than not 
criterion, a court may proceed through the evaluation using the 
following lines of inquiry: 
 
i. To what chemical was the plaintiff exposed? 
ii. Is there sufficient evidence in the scientific literature to 
support a causal relationship between exposure to the 
                                                          
risk and that the magnitude of the risk increases with increasing exposures. 
Regulators do not become concerned until lifetime (calculated) cancer risks 
reach probabilities of one-in-one million or greater. The no-threshold approach 
is not based on highly certain scientific knowledge, and there may be many 
exceptions to it. See RISK ASSESSMENT FORUM, supra note 21. 
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chemical and the specific type of injury or disease the 
plaintiff has incurred? 
If the answer to (ii), the general causation question, is no (using 
the scientific criteria for judging general causation from 
epidemiological studies, described above), then the inquiry ends. If 
the answer is to (ii) is yes, then the inquiry continues. It might also 
continue if the answer were “strong associations established, if not 
causation, and supporting evidence from experimental studies,” 
because additional evaluation might assist in dealing with such an 
ambiguity. Thus, the next inquiry: 
iii. What is the likelihood that someone having the 
plaintiff’s characteristics (age, sex, race, smoking habits, 
alcohol consumption rates, etc.) would have the specific 
injury or disease in the absence of exposure to the suspect 
chemical? 
Very few diseases or injuries have unique causes; most have 
multiple causes including, in our hypothetical case, the suspect 
chemical. Even if alternative causes are unknown, it may be 
understood that many individuals acquire the condition in the 
absence of exposure to the suspect chemical.51 Health statistics 
may be available to help answer inquiry (iii) with a reliable degree 
of quantification, especially in the case of cancer. Plaintiff’s 
condition may be vary rare, in which the likelihood of 
demonstrating specific causation (inquiry (iv), infra) increases; it 
becomes difficult to establish specific causation if the plaintiff’s 
condition is a very common one. Thus, this next inquiry: 
iv. Did the plaintiff incur exposures to the suspect chemical 
of sufficient magnitude and duration to make it more likely 
true than not that the chemical, and not some other factor, 
was the cause of the plaintiff’s medical condition? 
                                                          
51 Very few chemicals are known to be both necessary and sufficient causes 
of human disease. For example, although benzene is said by IARC to be a cause 
of certain types of human leukemias, it is by no means the only such cause and, 
in fact, most cases occur in the absence of benzene exposure. This same pattern 
exists for virtually all chemical carcinogens. See sources cited supra note 19 and 
infra note 54. 
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In the absence of some measure of exposure conditions,52 it is 
difficult, if not impossible, to establish specific causation. This 
conclusion stems from the fact that the risk of toxicity changes 
with dose and does not become even minimally significant until 
the threshold for toxicity is exceeded for sufficient periods of 
time.53 
It is not scientifically possible to determine, for a specific 
individual, what the threshold value is; but examination of the 
dose-response data from the epidemiological studies used to 
demonstrate general causation should reveal the magnitude of 
exposure necessary to increase risk above background levels.54 
Some have addressed the more likely true than not criterion by 
identifying, from the dose-response data, the so-called risk 
doubling dose: the dose required to double the background risk.55 
Thus, for example, if the specific plaintiff’s risk of developing his 
or her specific disease in the absence of exposure to the suspect 
chemical is one-in-one thousand, examination of the dose-response 
data from the epidemiological data can reveal the magnitude of the 
dose necessary to increase risk by a factor of one-in-one thousand. 
If the exposure experts can demonstrate that the plaintiff incurred 
                                                          
52 I.e., dose, duration, timing relative to injury, route of entry into the body, 
etc. See discussion supra Part I.A. 
53 See supra Part I.A. See also Philip S. Guzelian et al., Evidence-Based 
Toxicology: A Comprehensive Framework for Causation, 24  HUMAN AND 
EXPERIMENTAL TOXICOLOGY 161, 161-201 (2005).  This paper contains an 
excellent (though complex) discussion of the general problem of causation, as 
well as specific guidance regarding toxicological questions. 
54 Dose-response relationships identified in epidemiology studies provide 
information regarding the extent of disease risk increase that is associated with a 
given increment in exposure. Epidemiologists collect information on exposures 
incurred by the populations under study and typically distinguish subpopulations 
having exposures of different magnitudes and duration. Evidence that disease 
risk increases as exposure increases is used as supportive of a causal 
relationship. See GORDIS, supra note 18. See also sources cited supra note 21. 
55 Phillip Cole,  Causality in Epidemiology, Health Policy, and Law, 27 
ENVTL. LAW REP. 10279 (1997). In the determination of general causation, 
epidemiologists often use the risk-doubling criterion as a rule-of-thumb in 
establishing reliable statistical associations. This use of the criterion is different 
from that described here for examining specific causation. 
RODRICKS MACROED.DOC 4/25/2006  11:00 PM 
 DISEASE CAUSATION AND TOXIC SUBSTANCES 61 
 
exposures leading to a dose of at least that magnitude, then it can 
be concluded that exposure to the suspect chemical increased 
plaintiff’s disease risk to a level of at least two-in-one thousand 
(1/500). Thus, it may be concluded that, since the plaintiff actually 
has the disease, then the risk has been realized, and it is more 
likely that it was caused by the chemical than by whatever other 
factors cause the condition. This conclusion derives from the fact 
that, since the plaintiff’s risk was greater than two-in-one 
thousand, and that factors other than the suspect chemical 
contributed less than half of the plaintiff’s total risk (no more than 
one-in-one thousand), then there was a greater than 50% chance 
his or her condition was due to the chemical exposure and not 
other factors. If the exposure incurred by the plaintiff does not 
create a risk doubling dose, then under the criteria used here, it 
cannot be claimed specific causation has been demonstrated.56 
This sketch of how the analysis of specific causation may 
proceed is meant to describe the type of analysis necessarythe 
scientific method to be usedand is not intended to describe a 
strict set of inflexible criteria (such as, for example, a strict risk-
doubling standard). A degree of scientific judgment is necessarily 
involved, especially since the data required to conduct a careful, 
quantitative evaluation of the plaintiff’s exposures and 
epidemiological dose-response relationships are almost never 
without uncertainty. Alternative approaches, including what 
epidemiologists call attributable risk analysis (similar conceptually 
to what has been described but somewhat different in form) may 
also be applied. Whatever is undertaken in the analysis of specific 
causation, it should be clear that the mere fact that the plaintiff can 
demonstrate some exposure to a substance for which general 
causation has been established is hardly sufficient, even if that 
exposure exceeds some applicable regulatory standard. 
There is a role for additional analysis in certain cases, because 
it is possible that alternative and even more likely causes of a 
specific plaintiff’s harm can still be found, even if criteria for 
specific causation seem to be satisfied. This enters the domain of 
                                                          
56 Id. 
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what is sometimes called differential medical diagnosis, which I 
leave to others, except to say such diagnoses, whether they are 
intended to demonstrate causation or its lack, are by themselves 
inadequate evaluative tools.57 
IV. LIMITS IN PROVING CAUSATION 
The framework outlined for evaluating general and specific 
causation consists of elements that parallel those contained in the 
risk assessment framework used by regulatory agencies. It consists 
of an examination of the toxic effects produced by a chemical, the 
conditions of exposure necessary to produce those effects, the 
relationships between dose and effect, and the conditions under 
which humans (populations or individuals) have been or may 
become exposed. Some important differences between the types of 
scientific evidence used to conduct risk assessments in the tort and 
regulatory or public health contexts also exist, and the results from 
regulatory risk assessments will, in most cases, be of highly limited 
utility in the examination of individual disease causation. 
Although the general process described here for undertaking an 
evaluation of general and specific causation may have broad 
acceptance, it seems clear that nothing approaching the uniformity 
of scientific approaches that can be discerned in the regulatory 
context exists in connection with the evaluation of individual 
exposures and responses. The relative weights given to different 
types of scientific information may vary greatly among experts, 
and there appears to have been little substantive discussion of the 
problem of individual disease causation in the scientific, as against 
the legal, literature.58 
One issue that transcends the scientific literature concerns the 
question of the potentially excessive burden placed upon plaintiffs 
if they are required to show with a reasonable degree of scientific 
rigor that their injuries or diseases have been caused by chemical 
exposures. Although legal standards would seem to call for such 
                                                          
57 See sources cited supra note 26. 
58 A recent publication by Philip Guzelian and associates perhaps signals a 
break in this trend. Guzelian, supra note 53, at 161-201. 
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rigor, the data requirements necessary to apply appropriate 
scientific methods can sometimes be substantial, difficult, and 
costly to develop. Establishing general causality for any chemical 
requires extensive scientific investigation. Plaintiffs can, of course, 
incorporate existing scientific knowledge regarding those 
chemicals for which general causal relations with certain injuries 
or diseases have been established, but they are still required to 
develop evidence to support specific causation. For substances for 
which general causal relations have not been substantiated, it is 
difficult to imagine circumstances in which plaintiffs could 
develop such evidence. This conclusion must, however, be 
qualified by noting that it is premised on the view that establishing 
general causation requires the types of evidence described in this 
paper; clearly scientists may disagree on this matter. It is also 
likely that, in considering the types and strengths of different 
sources of scientific evidence necessary to establish causation, 
scientists can be influenced by their own, non-scientific views of 
how burdens of proof should be distributed between plaintiffs and 
defendants. 
A study of general and specific causation by The National 
Academies could be of high value. This institution, through reports 
of its expert committees, plays a leading role in the United States 
in developing scientific consensuses, and does so through 
processes that eliminate, to a high degree, the influence of 
individual biases. I suggest the scientific community would greatly 
benefit from the kind of guidance The National Academies 
provide, and the judicial system will in turn benefit from a clearer 
picture of the types of scientific evidence that are appropriate to 
bring before juries in matters such as those that are the subject of 
this paper. 
 
